Opulent
发表于 2025-3-21 17:34:19
书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector影响因子(影响力)<br> http://impactfactor.cn/2024/if/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector影响因子(影响力)学科排名<br> http://impactfactor.cn/2024/ifr/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector网络公开度<br> http://impactfactor.cn/2024/at/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector网络公开度学科排名<br> http://impactfactor.cn/2024/atr/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector被引频次<br> http://impactfactor.cn/2024/tc/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector被引频次学科排名<br> http://impactfactor.cn/2024/tcr/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector年度引用<br> http://impactfactor.cn/2024/ii/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector年度引用学科排名<br> http://impactfactor.cn/2024/iir/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector读者反馈<br> http://impactfactor.cn/2024/5y/?ISSN=BK0231141<br><br> <br><br>书目名称Competition Law and Policy in the Japanese Pharmaceutical Sector读者反馈学科排名<br> http://impactfactor.cn/2024/5yr/?ISSN=BK0231141<br><br> <br><br>
肌肉
发表于 2025-3-21 21:57:07
http://reply.papertrans.cn/24/2312/231141/231141_2.png
明智的人
发表于 2025-3-22 03:16:31
Competition and Cooperation: Building a Sustainable Healthcare Delivery System in a Society with a Dompetition policy. It then reviews the challenges the system faces. The chapter concludes by discussing the issues to be considered further when creating a sustainable healthcare delivery system and enacting competition policies.
租约
发表于 2025-3-22 07:00:39
Drug Regulation in Japan held liable arises. A remedial system for health damage caused by the proper use of medicinal products also exists. Although remedies are not limited to damage caused by unknown side effects, a certain set of requirements, different from that for civil liability, must be met to for the plaintiff to
cataract
发表于 2025-3-22 09:42:08
http://reply.papertrans.cn/24/2312/231141/231141_5.png
发誓放弃
发表于 2025-3-22 14:05:04
http://reply.papertrans.cn/24/2312/231141/231141_6.png
发誓放弃
发表于 2025-3-22 19:45:32
http://reply.papertrans.cn/24/2312/231141/231141_7.png
VICT
发表于 2025-3-22 23:07:28
http://reply.papertrans.cn/24/2312/231141/231141_8.png
有斑点
发表于 2025-3-23 01:47:01
http://reply.papertrans.cn/24/2312/231141/231141_9.png
OTHER
发表于 2025-3-23 06:11:22
2524-504X cal regulations and drug discovery. The chapters include comparative studies on Japanese regulations vs. those in the European Union and the United States...Japan is one of the biggest pharmaceutical markets in978-981-16-7816-5978-981-16-7814-1Series ISSN 2524-504X Series E-ISSN 2524-5058